420 related articles for article (PubMed ID: 31486978)
41. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.
Panni RZ; Sanford DE; Belt BA; Mitchem JB; Worley LA; Goetz BD; Mukherjee P; Wang-Gillam A; Link DC; Denardo DG; Goedegebuure SP; Linehan DC
Cancer Immunol Immunother; 2014 May; 63(5):513-28. PubMed ID: 24652403
[TBL] [Abstract][Full Text] [Related]
42. Hyaluronic Acid-Based Multilayer Films Regulate Hypoxic Multicellular Aggregation of Pancreatic Cancer Cells with Distinct Cancer Stem-Cell-like Properties.
Lee IC; Wu YC; Hung WS
ACS Appl Mater Interfaces; 2018 Nov; 10(45):38769-38779. PubMed ID: 30395429
[TBL] [Abstract][Full Text] [Related]
43. Novel therapeutic targets for pancreatic cancer.
Tang SC; Chen YC
World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
[TBL] [Abstract][Full Text] [Related]
44. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells.
Wang X; Liu Q; Hou B; Zhang W; Yan M; Jia H; Li H; Yan D; Zheng F; Ding W; Yi C; Hai Wang
PLoS One; 2013; 8(9):e73942. PubMed ID: 24040121
[TBL] [Abstract][Full Text] [Related]
45. [Pancreatic cancer stem cell].
Hamada S; Masamune A; Shimosegawa T
Nihon Rinsho; 2015 May; 73(5):844-9. PubMed ID: 25985641
[TBL] [Abstract][Full Text] [Related]
46. Heterogeneity and targeting of pancreatic cancer stem cells.
Penchev VR; Rasheed ZA; Maitra A; Matsui W
Clin Cancer Res; 2012 Aug; 18(16):4277-84. PubMed ID: 22896694
[TBL] [Abstract][Full Text] [Related]
47. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.
Suzuki S; Okada M; Sanomachi T; Togashi K; Seino S; Sato A; Yamamoto M; Kitanaka C
J Biol Chem; 2020 Dec; 295(52):18328-18342. PubMed ID: 33115754
[TBL] [Abstract][Full Text] [Related]
49. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
Su P; Yang Y; Wang G; Chen X; Ju Y
Int J Oncol; 2018 Sep; 53(3):1343-1353. PubMed ID: 29956726
[TBL] [Abstract][Full Text] [Related]
50. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
Modi SJ; Kulkarni VM
Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
[TBL] [Abstract][Full Text] [Related]
51. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
[TBL] [Abstract][Full Text] [Related]
52. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
54. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D
Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823
[TBL] [Abstract][Full Text] [Related]
55. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Zhou T; Liu J; Xie Y; Yuan S; Guo Y; Bai W; Zhao K; Jiang W; Wang H; Wang H; Zhao T; Huang C; Gao S; Wang X; Yang S; Hao J
Gut; 2022 Feb; 71(2):357-371. PubMed ID: 33674341
[TBL] [Abstract][Full Text] [Related]
56. Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
Dzobo K; Ganz C; Thomford NE; Senthebane DA
OMICS; 2021 Feb; 25(2):81-92. PubMed ID: 33170084
[TBL] [Abstract][Full Text] [Related]
57. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.
Shigdar S; Lin J; Li Y; Yang CJ; Wei M; Zhus Y; Liu H; Duan W
Ther Deliv; 2012 Feb; 3(2):227-44. PubMed ID: 22834199
[TBL] [Abstract][Full Text] [Related]
58. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
59. Cancer stem cells (CSCs), cervical CSCs and targeted therapies.
Huang R; Rofstad EK
Oncotarget; 2017 May; 8(21):35351-35367. PubMed ID: 27343550
[TBL] [Abstract][Full Text] [Related]
60. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
